Plus Therapeutics (NASDAQ:PSTV) Now Covered by Lake Street Capital

Lake Street Capital assumed coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Tuesday, Marketbeat reports. The firm issued a buy rating and a $2.00 price objective on the stock.

Several other research analysts have also weighed in on PSTV. Zacks Research lowered shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. D. Boral Capital cut their target price on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. HC Wainwright restated a “buy” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Plus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $5.80.

Plus Therapeutics Trading Down 0.6%

NASDAQ PSTV opened at $0.24 on Tuesday. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The stock has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.54. The company has a market capitalization of $33.41 million, a PE ratio of -0.13 and a beta of 0.89.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new position in shares of Plus Therapeutics during the 3rd quarter worth approximately $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter worth $100,000. Jane Street Group LLC bought a new position in Plus Therapeutics in the second quarter valued at $41,000. Finally, Altium Capital Management LLC bought a new position in Plus Therapeutics in the third quarter valued at $628,000. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.